194 related articles for article (PubMed ID: 32032721)
1. Novel Chimeric Immuno-Oncolytic Virus CF33-hNIS-antiPDL1 for the Treatment of Pancreatic Cancer.
Woo Y; Zhang Z; Yang A; Chaurasiya S; Park AK; Lu J; Kim SI; Warner SG; Von Hoff D; Fong Y
J Am Coll Surg; 2020 Apr; 230(4):709-717. PubMed ID: 32032721
[TBL] [Abstract][Full Text] [Related]
2. CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy.
Zhang Z; Yang A; Chaurasiya S; Park AK; Lu J; Kim SI; Warner SG; Yuan YC; Liu Z; Han H; Von Hoff D; Fong Y; Woo Y
Cancer Gene Ther; 2022 Jun; 29(6):722-733. PubMed ID: 34108669
[TBL] [Abstract][Full Text] [Related]
3. Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases.
Yang A; Zhang Z; Chaurasiya S; Park AK; Jung A; Lu J; Kim SI; Priceman S; Fong Y; Woo Y
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37019471
[TBL] [Abstract][Full Text] [Related]
4. PET imaging and treatment of pancreatic cancer peritoneal carcinomatosis after subcutaneous intratumoral administration of a novel oncolytic virus, CF33-hNIS-antiPDL1.
Zhang Z; Yang A; Chaurasiya S; Park AK; Kim SI; Lu J; Olafsen T; Warner SG; Fong Y; Woo Y
Mol Ther Oncolytics; 2022 Mar; 24():331-339. PubMed ID: 35118191
[TBL] [Abstract][Full Text] [Related]
5. Anti-Tumor Immunogenicity of the Oncolytic Virus CF33-hNIS-antiPDL1 against Ex Vivo Peritoneal Cells from Gastric Cancer Patients.
Zhang Z; Yang A; Chaurasiya S; Park AK; Kim SI; Lu J; Valencia H; Fong Y; Woo Y
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762490
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model.
Chaurasiya S; Yang A; Kang S; Lu J; Kim SI; Park AK; Sivanandam V; Zhang Z; Woo Y; Warner SG; Fong Y
Oncoimmunology; 2020; 9(1):1729300. PubMed ID: 32158622
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive preclinical study supporting clinical trial of oncolytic chimeric poxvirus CF33-hNIS-anti-PD-L1 to treat breast cancer.
Chaurasiya S; Yang A; Zhang Z; Lu J; Valencia H; Kim SI; Woo Y; Warner SG; Olafsen T; Zhao Y; Wu X; Fein S; Cheng L; Cheng M; Ede N; Fong Y
Mol Ther Methods Clin Dev; 2022 Mar; 24():102-116. PubMed ID: 35024377
[TBL] [Abstract][Full Text] [Related]
8. Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose.
O'Leary MP; Choi AH; Kim SI; Chaurasiya S; Lu J; Park AK; Woo Y; Warner SG; Fong Y; Chen NG
J Transl Med; 2018 Apr; 16(1):110. PubMed ID: 29699566
[TBL] [Abstract][Full Text] [Related]
9. Novel therapy for anaplastic thyroid carcinoma cells using an oncolytic vaccinia virus carrying the human sodium iodide symporter.
Gholami S; Haddad D; Chen CH; Chen NG; Zhang Q; Zanzonico PB; Szalay AA; Fong Y
Surgery; 2011 Dec; 150(6):1040-7. PubMed ID: 22136819
[TBL] [Abstract][Full Text] [Related]
10. Enhancing Expression of Functional Human Sodium Iodide Symporter and Somatostatin Receptor in Recombinant Oncolytic Vaccinia Virus for In Vivo Imaging of Tumors.
Wang J; Arulanandam R; Wassenaar R; Falls T; Petryk J; Paget J; Garson K; Cemeus C; Vanderhyden BC; Wells RG; Bell JC; Le Boeuf F
J Nucl Med; 2017 Feb; 58(2):221-227. PubMed ID: 27635026
[TBL] [Abstract][Full Text] [Related]
11. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
Nelson A; Gebremeskel S; Lichty BD; Johnston B
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
[TBL] [Abstract][Full Text] [Related]
12. Using Oncolytic Virus to Retask CD19-Chimeric Antigen Receptor T Cells for Treatment of Pancreatic Cancer: Toward a Universal Chimeric Antigen Receptor T-Cell Strategy for Solid Tumor.
Chen C; Park AK; Monroy I; Ren Y; Kim SI; Chaurasiya S; Priceman SJ; Fong Y
J Am Coll Surg; 2024 Apr; 238(4):436-447. PubMed ID: 38214445
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
Kajiwara Y; Tazawa H; Yamada M; Kanaya N; Fushimi T; Kikuchi S; Kuroda S; Ohara T; Noma K; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T
Cancer Immunol Immunother; 2023 May; 72(5):1285-1300. PubMed ID: 36436021
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy using therapeutic and diagnostic recombinant oncolytic vaccinia virus GLV-1h153 for management of colorectal peritoneal carcinomatosis.
Eveno C; Mojica K; Ady JW; Thorek DL; Longo V; Belin LJ; Gholami S; Johnsen C; Zanzonico P; Chen N; Yu T; Szalay AA; Fong Y
Surgery; 2015 Feb; 157(2):331-7. PubMed ID: 25616946
[TBL] [Abstract][Full Text] [Related]
15. A Novel Chimeric Poxvirus Encoding hNIS Is Tumor-Tropic, Imageable, and Synergistic with Radioiodine to Sustain Colon Cancer Regression.
Warner SG; Kim SI; Chaurasiya S; O'Leary MP; Lu J; Sivanandam V; Woo Y; Chen NG; Fong Y
Mol Ther Oncolytics; 2019 Jun; 13():82-92. PubMed ID: 31061881
[TBL] [Abstract][Full Text] [Related]
16. Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer.
Grekova SP; Aprahamian M; Daeffler L; Leuchs B; Angelova A; Giese T; Galabov A; Heller A; Giese NA; Rommelaere J; Raykov Z
Cancer Biol Ther; 2011 Nov; 12(10):888-95. PubMed ID: 22024742
[TBL] [Abstract][Full Text] [Related]
17. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
18. An oncolytic poxvirus encoding hNIS, shows anti-tumor efficacy and allows tumor imaging in a liver cancer model.
Chaurasiya S; Valencia H; Zhang Z; Kim SI; Yang A; Lu J; Woo Y; Warner SG; Ede NJ; Fong Y
Mol Cancer Ther; 2023 May; 22(7):882-90. PubMed ID: 37196156
[TBL] [Abstract][Full Text] [Related]
19. Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting.
Clubb JHA; Kudling TV; Girych M; Haybout L; Pakola S; Hamdan F; Cervera-Carrascon V; Hemmes A; Grönberg-Vähä-Koskela S; Santos JM; Quixabeira DCA; Basnet S; Heiniö C; Arias V; Jirovec E; Kaptan S; Havunen R; Sorsa S; Erikat A; Schwartz J; Anttila M; Aro K; Viitala T; Vattulainen I; Cerullo V; Kanerva A; Hemminki A
Front Immunol; 2023; 14():1060540. PubMed ID: 36817448
[TBL] [Abstract][Full Text] [Related]
20. A novel oncolytic viral therapy and imaging technique for gastric cancer using a genetically engineered vaccinia virus carrying the human sodium iodide symporter.
Jun KH; Gholami S; Song TJ; Au J; Haddad D; Carson J; Chen CH; Mojica K; Zanzonico P; Chen NG; Zhang Q; Szalay A; Fong Y
J Exp Clin Cancer Res; 2014 Jan; 33(1):2. PubMed ID: 24383569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]